Lorazepam injection vials recalled nationwide for manufacturing specification failures
Hikma Pharmaceuticals is recalling approximately 4.7 million vials of Lorazepam injection nationwide after finding out-of-specification related compounds during quality testing. The affected lots expire between June and August 2023.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for failed manufacturing specifications with no reported illnesses or injuries. Out-of-specification impurities and degradation products in an injectable benzodiazepine constitute a risk-of-harm product where injury has not yet been reported, meeting the High severity criterion.
Plain-English summary
Lorazepam injection, USP 2mg/mL is being recalled by Hikma Pharmaceuticals USA Inc. due to failed quality control specifications. Testing of retained samples identified out-of-specification results for total related compounds (impurities and degradation products) in the product.
The recall affects approximately 4.7 million vials distributed nationwide. The affected lot numbers are 060064 (expires June 2023), 070084 (expires July 2023), 070126 (expires July 2023), 080091 (expires August 2023), and 080060 (expires August 2023).
Lorazepam is a prescription injectable benzodiazepine medication. Patients and healthcare providers should verify if they have affected lots and contact their pharmacy or healthcare provider for guidance on replacement or alternative products.
No illnesses or injuries related to this recall have been reported to date.
The recalled product
- Product
- LORAZEPAM (LORAZEPAM)
- Brand
- LORAZEPAM
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Category
- Drug — Injectable benzodiazepine
- Hazard
- impurities
- degradation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot # 060064
- Exp. 06/2023
- 070084
- Exp. 07/2023
- 070126
- 080091
- Exp. 08/2023
- 080060
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LORAZEPAM
- HighLorazepam Tablets Recalled Due to Sub-Potency and Failed Stability Testing
FDA (Drugs) · 2025-02-26
- HighLorazepam Tablets Recalled for Failed Impurity and Potency Specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam injection vials recalled for elevated impurities and degradation
FDA (Drugs) · 2023-05-24
- HighLorazepam Injection Recalled for Out-of-Specification Impurities and Degradation
FDA (Drugs) · 2022-08-17
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27